Search

Displaying results 4231 - 4240 of 8700 in total
  1. Drug

    Didecyldimethylammonium

    go.drugbank.com/drugs/DB04221
    ApprovedInvestigational

    Mixtures: Septi-san
  2. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    Targeting IL-6 function can be achieved directly, or through interrupting the IL-6 receptor or gp130 receptor axes. … Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system.

  3. Drug

    Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10990
    Approved

    a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primarly immunization. … Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received

  4. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD). … RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801.

  5. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    While cannabis in its natural plant form is currently used "off-label" for the management of many medical conditions, THC is currently commercially available in synthetic form as [DB00486], as purified … Sativex® is available in a 1:1 formulation of THC:CBD as an oro-mucosal pump spray used for treatment of neuropathic pain from Multiple Sclerosis (MS) and for intractable cancer pain.

    Categories: Cannabinoid Receptor Agonists, Cytochrome P-450 Substrates
  6. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

    Categories: Agents for Dermatitis, Excluding Corticosteroids, Cytochrome P-450 Substrates
  7. Drug

    Carteolol

    go.drugbank.com/drugs/DB00521
    Approved

    A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  8. Drug

    Cyd dengue virus serotype 1 live (attenuated) antigen

    go.drugbank.com/drugs/DB15521
    ApprovedInvestigationalWithdrawn

    Mixtures: DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
  9. Drug

    Cyd dengue virus serotype 2 live (attenuated) antigen

    go.drugbank.com/drugs/DB15522
    ApprovedInvestigationalWithdrawn

    Mixtures: DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
  10. Drug

    Valrubicin

    go.drugbank.com/drugs/DB00385
    Approved

    It is a semisynthetic analog of the [doxorubicin], which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.